Pain Management

Bill McCarberg, MD

Founder Chronic Pain Management Program Kaiser Permanente San Diego (retired)

Adjunct Assistant Clinical Professor University of California School of Medicine San Diego

President Western Pain Society

The Problem

- 110,000 million chronic pain patients in the United States (2011 Institute of Medicine Report)
- 6000 pain specialists
- 120,000 primary care providers


Why It Hurts

Pain is protective and vital to survival

- Alerting system
- Signals damage or danger
- Hereditary sensory and autonomic neuropathy Type IV; lack A-delta and C fibers

Normal pain described as eudynia

Normal Pain Pathways in the Dorsal Horn



Mannion RJ, Woolf CJ. *Clin J Pain*. 2000;16(suppl 3):S144-S156.

Why It Hurts

Anatomy and pain pathways key to relieving pain

- Discover source of pain
- Do something to the source or pathways
 - rest, ice, topical agents, medication, injection, surgery
 - alternatives acupuncture, herbals
 - block or interrupt sign rhizotomy, cordotomy

Successful outcomes

Why It Hurts

- Sometimes pain does not improve in healing of tissues
- Source had not been identified
 - Look harder better understanding of pathways, better tools

animal studies, scans, biopsies, single nerve experiments, PET



Patient A - Low pain threshold Normal MRI of spine Severe back pain Patient B - High pain threshold Prominent bulging disc No pain or symptoms


Barriers to Treatment

- Knowledge
- Regulation
- Bias

Chronic Pain Conundrum

The most difficult issue now facing physicians "...whether and how to prescribe opioid therapy for chronic pain that is not associated with terminal disease, including pain experienced by the increasing number of patients with cancer in remission."

Top Concerns Among PCPs (N=248)



Opioids in Chronic Pain

Strong push to use more opioids

- Federation of State Medical Boards
- Medical Boards encourage use Intractable Pain Acts

Opioid Analgesia—1990s

Old Teaching

- 1. All patients get addicted to narcotics
- 2. Side effects limit effectiveness
- 3. Save until pain is really bad—tolerance
- 4. Pain is not life threatening

New Thoughts

- 1. Almost no one gets addicted to opioids
- 2. Side effects can be managed
- 3. Treat pain early tolerance is exaggerated

4. Pain kills

Opioid Analgesia—2000-2012


Old Teaching

- 1. All patients should be given a trial of opioids
- 2. No ceiling effects for opioids
- 3. High pain levels require opioids as first-line agents
- 4. Even addicts do well on opioid therapy

New Thoughts

- 1. In some patients, risks may be too high for opioids
- 2. As doses increase, effects lessen; hypersensitization
- 3. Pain levels alone do not dictate opioids
- 4. Significant practice issues in monitoring patients on opioids

Hydrocodone/APAP is the Most Prescribed Opioid and the Most Prescribed Product in US



Opioids in Chronic Pain


Strong push to use more opioids

- Federation of State Medical Boards
- Medical Boards encourage use Intractable Pain Acts
- Still controversial
 - Increased use and awareness of prescription drug abuse
 - Physician and, patient fear, bias, misunderstanding
 - Regulatory oversight

Pain, Abuse, Misuse and Diversion



New Illicit Drug Use in the United States: 2005



*526,000 new nonmedical users of OxyContin[®]. SAMHSA, OAS. NSDUH, 2005. Available at: www.oas.samsa.gov/nsduh.htm. Accessed February 15, 2007.

Does Prescribing Drive Opioid Abuse?

- 30% to 45% of prescription opioid abusers report their first opioid prescription was from a doctor for pain¹
- Prevalence of comorbid substance abuse among pain patients on opioids is 20% to 40%²
- Most prescription opioid abusers obtain drugs from either their own prescriptions or those of friends and family⁴
- Majority of abusers were at apparent high risk prior to first exposure³

¹Potter JS et al. *Drug Alcohol Depend*. 2004;76:213-215; ²Hays LR. *J Addict Dis.* 2004;23:1-9; ³Jamison RN et al. *J Pain Symptom Manage*. 2000;19:53-62; ⁴Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings). Rockville, MD; 2010.

Risk Evaluation and Mitigation Strategy (REMS)

- Engine behind REMS is misuse, abuse, addiction, diversion and death (political in election year)
- Unintended consequence patients, providers
- Voluntary program targeting all prescribers of long-acting opioids – 2-3 hours of training
- 350,000 DEA registrants who prescribe Schedule 2 drugs (long acting opioids)
- Goal is 25% in first year
- If education goal is not achieved, may become mandatory

DEA, Drug Enforcement Administration http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm

- 77-year-old woman with osteoarthritis of the hip taking 3 hydrocodone tablets/week
- States that she would take more but is worried about addiction
 - Need to know environment; who is living with patient

- 45-year-old man with failed back syndrome on 8 oxycodone/acetaminophen tablets daily
- Always shows up for office visits appearing appropriate, never calls in early or reports lost pills
- Continues to work in construction because he "has to"


- 55-year-old man with diabetic peripheral neuropathy with A₁C of 10.2% despite your best efforts (nonadherence)
- Oxycodone ER 80 mg 2 to 3 times daily plus hydrocodone/acetaminophen 10/325 mg 10 times daily
- Social Security disability and constantly testing you about early refills, lost medication
- Wife on Social Security disability and takes opioids for fibromyalgia

- 47-year-old man with low back pain new to your office and out of medication on Friday afternoon
- Requesting refills on medication
 - Methadone 10 mg 4 qid
 - Oxycodone 15 mg 3 tid
 - Carisoprodol 2 qid
 - Valium 10 mg 2 bid

Assessment Issues

- How did we get from a 77-year-old taking 3 hydrocodone tablets/week to a 47-year-old on multiple medications without and old record?
- Risk assessment
 - Why
 - How
- Strategy to deal with risk
 - Refer how can you be involved in this care
 - Increase surveillance

Population of Prescription Opioid Users Is Heterogeneous



Assessment

- Detect comorbid psychiatric illness
- Develop a management plan
- Ideally, the patient will agree to adhere to the treatment plan
 - Complete abstinence from illicit drug use may be unrealistic

Assessment Parameters

- History
- Screening tools
- Pill counts, urine drug testing
- Prescription monitoring programs
- Specialty help when available

Screening Instruments

- Several clinical tools are available that estimate risk of noncompliant opioid use^{1,2,3}
- The results determine how closely a patient should be monitored during the course of opioid therapy³
 - Scores implying a high risk of abuse are not reasons to deny pain relief³

¹Webster LR, Webster RM. *Pain Med.* 2005;6:432-442; ²Coambs RE et al. *Pain Res Manage.* 1996;1:155-162; ³Butler SF et al. *Pain.* 2004;112:65-75.

Tools to Measure Risk

- Screener and Opioid Assessment for Patients with Pain (SOAPP)¹
- Diagnosis, Intractability, Risk Efficacy (DIRE)²
- Opioid Risk Tool (ORT)³
- Screening, Brief Intervention, and Referral to Treatment (SBIRT)⁴
- Current Opioid Misuse Measure (COMM)⁵

¹Butler SF et al. *Pain.* 2004;112:65-75; ²Belgrade MJ et al. *J Pain.* 2006;7:671-681; ³Webster LR, Webster RM. *Pain Med.* 2005;6:432-442; ⁴Vaca FE, Winn D. *West J Emerg Med.* 2007;8:88-92; ⁵Butler SF et al. *Pain.* 2007;130:144-156.

Opioid Risk Tool

			Administration
 Family hx of substance abuse Alcohol Illegal drugs Prescription drugs 	 1 2 4 	□ 3 □ 3 □ 4	 On initial visit Prior to opioid therapy Scoring (risk)
2. Personal hx of substance abuse Alcohol Illegal drugs Prescription drugs	□ 3 □ 4 □ 5	□ 3 □ 4 □ 5	 0-3: low (6%) 4-7: moderate (28%) >8: high (>90%)
3. Age between 14-45 yrs	1	1	Pro- Commence of the
4. Hx of preadolescent sexual abuse	3	0	2/ 01
5. Psychologic disease ADD, OCD, bipolar, schizophrenia Depression	□ 2 □ 1	□ 2 □ 1	
Scoring totals	5:		1 19
ADD, attention deficit disorder; Hx, history; OCD, obsessive-compulsive disorder Webster LR, Webster RM. <i>Pain Med.</i> 2005;6:432-442.			

Accuracy in Predicting Discharge for Aberrant Drug-Related Behaviors

Measure Accuracy Rate	<u>%</u>
Clinical interview	77%
SOAPP	72%
ORT	45%
DIRE	17%

DIRE, Diagnosis, Intractability, Risk, and Efficacy inventory; ORT, Opioid Risk Tool; SOAPP, Screener and Opioid Assessment for Patients with Pain Moore TM et al. *Pain Med.* 2009;10:1426-1433.

Urine Drug Testing – Good Review

• Christo PJ et al. Urine drug testing in chronic pain. *Pain Physician*. 2011;14:123-143.

Why Urine Drug Testing in Pain Management?

- Adjunct to patient self-reporting (unreliable)
- Validates, de-stigmatizes
- Assists in confirming
- May unmask
 - Addiction
 - Pseudo-addiction
 - Drug diversions
 - Self-medication for other illnesses
- Several available at NHC
 - Pain not occupational
 - Expensive

Interpreting Urine Drug Tests

- Know what to expect and how to interpret results
- Parent compound and or metabolite should show up in the urine
 - Oxycodone oxymorphone
 - Hydrocodone hydromorphone
 - Codeine morphine
- Is the substance present that you expect?
- Are there substances present that you do not expect?

Positive and Negative Urine Toxicology Results

- Positive forensic testing
 - Legally prescribed medications
 - Over-the-counter medications
 - Illicit drugs or unprescribed medications
 - Substances that produce the same metabolite as that of a prescribed or illegal substance
 - Errors in laboratory analysis

Negative compliance testing

- Medication bingeing
- Diversion
- Insufficient test sensitivity
- Failure of laboratory to test for desired substances



Detection Times of Common Drugs of Misuse


Drug	Approximate Retention Time		
Amphetamines	48 hours		
Barbiturates	 Short-acting (eg, secobarbital), 24 hours Long-acting (eg, phenobarbital), 2-3 weeks 		
Benzodiazepines	 3 days if therapeutic dose is ingested Up to 4-6 weeks after extended dosage (≥ 1 year) 		
Cannabinoids	 Moderate smoker (4 times/week), 5 days Heavy smoker (daily), 10 days Retention time for chronic smokers may be 20-28 days 		
Cocaine	 2-4 days, metabolized 		
Ethanol	• 2-4 hours		
Methadone	Approximately 30 days		
Opiates	• 2 days		
Phencyclidine	 Approximately 8 days Up to 30 days in chronic users (mean value = 14 days) 		
Propoxyphene	• 6-48 hours Gourlay DL, Heit HA. Pain Med. 2009;10 Suppl 2:S115-123.		

Drug Cross-Reactants


Drug	Cross-Reactant
Cannabinoids	NSAIDs, dronabinol, pantoprazole
Opioids	Poppy seeds, chlorpromazine, rifampin, dextromethorphan quinine
Amphetamines	Ephedrine, methylphenidate, trazodone, bupropion, desipramine, amantadine, ranitidine, phenylpropanolamine,
PCP	Chlorpromazine, thioridazine, meperidine, dextromethorphan, diphenhydramine, doxylamine
Benzodiazepine	Oxaprozin, some herbal agents
Ethanol	Asthma inhalers (in some cases)
Methadone	Propoxyphene, quetiapine

NSAIDs, nonsteroidal anti-inflammatory drugs; PCP, phencyclidine Manchikanti L et al. *Pain Physician*. 2008;11:S155-S180.

State Prescription Drug Monitoring Programs Status, 2003



State Prescription Drug Monitoring Programs Status, July 2012



National Alliance for Model State Drug Laws. Status of State Prescription Monitoring Programs - State Map. July 2012. Reprinted with permission. © 2012 The National Alliance for Model State Drug Laws (NAMSDL).

CURES: Prescription Drug Monitoring California

CURES: Acronym for the Controlled Substance Utilization Review and Evaluation System

https://pmp.doj.ca.gov/pdmp/index.do

State of California Department of Justice

Office of the Attorney General



Kamala D. Harris

Attorney General

AG Home Page

Tools & Resources

Health Information Privacy (HIPAA Guidelines) FAQ's PDMP (CURES)

-User Agreement-

The California Prescription Drug Monitoring Program (PDMP), **CURES**, is committed to assisting in the reduction of pharmaceutical drug diversion without affecting legitimate medical practice and patient care. The CURES system is designed to identify and deter drug abuse and diversion through accurate and rapid tracking of Schedule II through IV controlled substances. The role of the PDMP entrusts that well informed prescribers and pharmacists can and will use their professional expertise to evaluate their patients care and assist those patients who may be abusing controlled substances.

The information obtained herein is only made available to Practitioners, Pharmacists, Law Enforcement, and Regulatory Boards as specified under Health and Safety (H&S) Code Section 11165(a) by the Department of Justice, Bureau on Narcotic Enforcement. All users of the PDMP system shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients as specified under H&S Code Section 11165(c). Any request for or release of controlled substance history shall be made in accordance with the Department of Justice guidelines, and is subject to the provisions of the Confidentiality of the Medical Information Act (Civil Code 56 et seq.).

Dissemination or distribution of this information to anyone other than the registered user is strictly prohibited. Disciplinary, civil or criminal actions will be taken by the Department of Justice and/or appropriate Regulatory Board.

HIPAA and all confidentiality and disclosure provisions of California Law cover the information contained in this database. All users must comply with HIPAA Privacy Rule Requirements when using the Prescription Monitoring Program System. US Department of Health and Human Services, HIPAA guidelines are located at <u>http://www.hhs.gov/ocr/privacy/</u>

By Logging into the PDMP system you understand and agree to the above terms.

Login Information —	
Username	
Password	case-sensitive
	Login
	Forgot password New users register here

Skip to conte

State of t	California Depai	rtment <i>of</i> Justice	e	Kamala D. Harris		
Off	fice <i>of the</i> Attorn	ney General		Attorney General		
Home Page	PDMP Home Page	Patient Activity Rep	ort	Change Password	HELP	Logout
Tools & Patient Activ	& Resources		he PDMP Applicat	tion	Logged	in, bimcca
20000000 R	s of Prescriptions	The California Presc of pharmaceutical dn CURES program, res following numerous la The CURES system rapid tracking of Sch and educational tool community. The Prescription Dru healthcare prescriber and regulatory board	ug diversion without affecting leg tructured in 2003 and evolved fr egislative enactments. is designed to identify and dete edule II through IV controlled su for law enforcement, regulatory g Monitoring Program system al 's and pharmacists authorized to s to access timely patient presc	, CURES, is committed to assisting in the r gitimate medical practice and patient care. rom the California Triplicate Prescription Pro er drug abuse and diversion through accurate ubstances. It is a valuable investigative, pre boards, educational researchers, and the he llows pre-registered users including licensec o dispense controlled substances, law enfor oription history information to better identify the Prescription Drug Monitoring Program er	The ogram e and eventive ealthcare d rcement, and	
		their patients care an Dissemination or dist	d assist those patients who ma tribution of this information to an ry, civil or criminal actions will b ry Board.	and will use their professional expertise to e ny be abusing controlled substances. nyone other than the registered user is strict se taken by the Department of Justice and/o	tly	
		08-02-2011	Counterfeit Prescriptions San Die	ero Alert 15		
		08-02-2011	Fraudulent Prescriptions San Die			
		08-02-2011	Fraudulent Prescriptions San Die	ego Alert 17		
		08-02-2011 08-02-2011	Fraudulent Prescriptions San Die Fraudulent Prescriptions San Die	· · · · · · · · · · · · · · · · · · ·		

State <i>of</i> California Depa Office <i>of the</i> Attorn			Kamala D. Harris ∝ Attorney General	
AG Home Page PDMP Home Page	Patient Activity Report		Change Password	HELP Logout
Tools & Resources Patient Activity Report Theft or Loss of Prescriptions FAQ's	Patient/Client A * Indicates Required Fiel Client Last Name* Date of Birth* Address City Period in Months*	Ids First Na mm/dd/yyyy G	ame*	Logged in, bimccarb
	[Search Mode-		
		Search Mode • Partial match		
		the penalty of perjury, that I am a li ithorized to obtain the above mention controlled substance history Search Rese	ned patient's dispensed	

Low Back Pain Initial Presentation

- 52-year-old presents with acute low back pain
- Patient reports he has had recurrent minor injuries which resolve quickly
- Current pain is 6/10 in the right low back radiating down right leg to lateral foot
- Examination is unremarkable except for right of midline tenderness at L5-S1 and a positive right straight leg raise
- Prescribed stretches, rest, ice, anti-inflammatory, muscle relaxant
- Off work 7 days due to physical job and no availability of modified duty
- Follow-up appointment scheduled for 1 week

Low Back Pain, First Follow-Up Visit

- Pain does not resolve in 1 week
- Patient now reports that due to the pain, he has had a disruption of sleep, mood, and his hobbies – irritable
- Hydrocodone/acetaminophen prescribed, more time off work (2 weeks), and physical therapy is ordered

Low Back Pain, Second Follow-Up Visit

- 2 weeks later mild improvement in sleep with hydrocodone/acetaminophen
- Pain is 5/10 with decreased radiation in the right leg, and he is able to move around the house more
- Patient is walking daily, but still unable to return to his physically demanding job
- Referred to physical medicine subspecialist

Low Back Pain, Third Follow-Up Visit

- Pain 6/10 mainly axial low back pain on the right
- Pain radiates to right leg with prolonged standing or walking
- Sleep, mood, hobbies all disrupted
- Lost job, now on disability
- Has been on anti-inflammatories, muscle relaxants, hydrocodone for 6 weeks

What Are the Requirements and How Should They Be Implemented

- Diabetes has measurable outcomes and national standards
- Pain management has no applicable standards only guidelines

Federation of State Medical Boards

- 2004 Model Policy for the Use of Controlled Substances for the Treatment of Pain
- 28 state medical boards have adopted the model policy verbatim, and 10 other states have adopted guidelines with similar language
 - **1.** Evaluation of the patient
 - 2. Treatment plan
 - **3.** Informed consent and agreement for treatment
 - 4. Periodic review
 - **5.** Consultation
 - 6. Medical records
 - 7. Compliance with controlled substances laws and regulations

Medical Record Should Contain 10 Parts

- **1.** History and physical examination
- **2.** Diagnostic, therapeutic, and laboratory results
- **3.** Evaluation and consultation
- 4. Treatment objectives
- 5. Discussion of risks and benefits of treatment
- 6. Informed consent
- 7. Treatment offered
- 8. Medication type, date, dosage, quantity
- 9. Instructions and treatment agreement
- **10.** Periodic review

52-Year-Old Patient With Chronic Low Back Pain

 Wife reports to their family physician that her husband is now excessively consuming alcohol at night. He slurs his speech, has fallen down, and he is verbally abusive

Wife's Report

- Important collateral information
 - Importance of opioid agreement to talk to spouse, family
- Opioid agreement
 - Understanding about other drug use including alcohol, marijuana
- Information
 - Alcohol problem
 - Makes treatment more difficult
- Discuss with patient
 - Referral

Fourth Follow-Up Visit and Chart Note

- Always been anxious, even as a child
- Positive family history for depression
- Previous episodes of depression resulted in loss of job
- Patient states that medication helps decrease pain and increase function, but it also helps him handle anxiety and sleep better
- Experimented with alcohol and marijuana when younger and improved anxiety, but
 - "I did not like taking that illegal stuff"
 - "Besides, it really messed up my family"

Fourth Follow-Up Visit and Chart Note

- Overuse of alcohol reported
- Discussed with patient
 - Patient agreed to stop all alcohol
 - Agreed to attend Alcoholics Anonymous
- Patient's pain has decreased, and function has improved on current regimen
- Urine drug test
- Consider chemical dependency referral

Opioid Risk Tool

			Administration
 Family hx of substance abuse Alcohol Illegal drugs Prescription drugs 	Female 1 2 4	Male x 3 x 3 I 4	 On initial visit Prior to opioid therapy
2. Personal hx of substance abuse Alcohol Illegal drugs Prescription drugs	 3 4 5 	x 3 x 4 □ 5	<u>Scoring</u> (risk) • 0-3: low (6%) • 4-7: moderate (28%)
3. Age between 14-45 yrs	1	1	• <u>></u> 8: high
4. Hx of preadolescent sexual abuse	3	0	(>90%)
5. Psychologic disease ADD, OCD, bipolar, schizophrenia Depression	□ 2 □ 1	□ 2 x 1	
Scoring totals	:	14	
ADD, attention deficit disorder; Hx, history; OCD, obsessive Webster LR, Webster RM. <i>Pain Med.</i> 2005;6:432-442.	-compulsive disc	order	55

Federation of State Medical Boards

- 2004 Model Policy for the Use of Controlled Substances for the Treatment of Pain
- 28 state medical boards have adopted the model policy verbatim, and 10 other states have adopted guidelines with similar language
 - **1.** Evaluation of the patient
 - 2. Treatment plan
 - **3.** Informed consent and agreement for treatment
 - 4. Periodic review
 - **5.** Consultation
 - 6. Medical records
 - 7. Compliance with controlled substances laws and regulations

Medical Record Should Contain 10 Parts

- **1.** History and physical examination
- **2.** Diagnostic, therapeutic, and laboratory results
- **3.** Evaluation and consultation
- 4. Treatment objectives
- 5. Discussion of risks and benefits of treatment
- 6. Informed consent
- 7. Treatment offered
- 8. Medication type, date, dosage, quantity
- 9. Instructions and treatment agreement
- **10.** Periodic review

Summary

- REMS is coming
- Opioid abuse is a problem
- Unintended consequences could be devastating
- Primary care has to do a better job
- Consultations especially psychosocial services vital to increase primary care competence and comfort